Clinical Report: Efgartigimod for Managing Myasthenia Gravis-Myositis Overlap Syndrome
Overview
This case study reports the use of efgartigimod in a patient with ICI-related myasthenia gravis-myositis overlap syndrome. The patient showed improvement after treatment, with normalization of creatine kinase levels and reduction in symptom severity.
Background
Immune checkpoint inhibitors (ICIs) can lead to neurological complications, including myasthenia gravis (MG)-myositis overlap syndrome. This condition poses diagnostic challenges and may not respond to standard treatments such as high-dose corticosteroids and intravenous immunoglobulin. Efgartigimod, a neonatal Fc receptor blocker, is being investigated as a therapeutic option in this context.
Data Highlights
Parameter
Before Treatment
After Treatment
Creatine Kinase (U/L)
553.82
Normal (specific value not provided)
Activities of Daily Living (ADL) Score
10
1
Quantitative Myasthenia Gravis (QMG) Score
16
5
Key Findings
A 69-year-old female developed ICI-related MG-myositis overlap syndrome after tislelizumab therapy.
Clinical symptoms included bilateral ptosis, dysarthria, and limb weakness.
Standard treatments were ineffective, leading to the use of efgartigimod.
After four infusions of efgartigimod, clinical improvement was observed.
The patient reported no adverse events at the 5-month follow-up.
Clinical Implications
Efgartigimod may offer a promising alternative for patients with ICI-related MG-myositis overlap syndrome who do not respond to conventional therapies. Further studies are needed to establish its efficacy and safety in larger cohorts.
Conclusion
This case illustrates the use of efgartigimod in a patient with ICI-related MG-myositis overlap syndrome, highlighting the need for further investigation.
